FC)R	Μ	4
----	----	---	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1												
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VTGN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Singh Shawn	<u>.</u>			<u>oen merape</u>	<u>unco, me</u>		X	Director	10% 0	Dwner		
(Last) C/O VISTAGEN 343 ALLERTON		(Middle) UTICS, INC.	3. Date 02/02/	of Earliest Transac 2018	tion (Month/D	ay/Year)	X	Officer (give title below) CHIEF EXECU	below	,		
(Street) SOUTH SAN	CA	94080	4. If Am	endment, Date of C	Driginal Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Form filed by One				
FRANCISCO								Form filed by Mor Person	re than One Repo	orting		
(City)	(State)	(Zip)										
		Table I - Nor	n-Derivative S	ecurities Acqu	uired, Disp	osed of, or Benefic	cially (Owned				
1. Title of Security (Instr. 3) Date (Month/L				2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial		

	Month/Day/Year)		8)				3, 4 and 5)	Beneficially	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)	
											٦

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exerc Expiration Da (Month/Day/Y	te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Securities Underlying Derivative Security		8. Price of Derivative Security (Instr. 5)	e derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$1.16	02/02/2018		A		300,000		(1)	02/02/2028	Common Stock	300,000	\$0	300,000	D			

Explanation of Responses:

1. 25% of the Shares subject to the Option shall vest on date of grant February 2, 2018, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter.

<u>/s/ Jerrold D. Dotson, Attorney-</u> in-Fact

<u>, Attorney-</u> <u>02/05/2018</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.